Neurotech gets another approval around autism.

Neurotech International (ASX:NTI) has obtained Human Research Ethics Committee (HREC) approval to extend the Phase I/II clinical trial in autism spectrum disorder (ASD) by another 52 weeks.

The extension for the trial was based on requests from the lead investigator, patients and their caregivers to extend the duration of treatment.

"This 2nd long term extension to our core clinical program which commenced in mid 2022 and reported 52 week safety and efficacy data in March 2023 reflects the significant progress my patients have made, and their caregivers strong desire to continue treatment over the long term."

"The lack of side effects with NTI164 and the significant clinical improvements we've observed in these patients necessitates a long term treatment plan."

Professor Michael Fahey, Head of the Paediatric Neurology Unit at Monash Medical Centre.

NTI164 is an orally administered "full spectrum" medicinal cannabis plant extract containing 0.08% THC.